We independently reviewed the major U.S. telehealth providers offering tirzepatide — both brand-name (Mounjaro®, Zepbound®) and compounded — and ranked them on a fixed methodology applied uniformly. SURMOUNT-1 demonstrated tirzepatide produces 22.5% mean weight loss at 72 weeks, the highest of any FDA-approved or compounded weight management medication.
Scored against our 100-point rubric on flat-rate pricing transparency, dual 503A/503B pharmacy disclosure, MD/DO oversight, and patient outcomes.
Each provider scored on five fixed dimensions: pricing transparency (25%), clinical protocols (25%), prescriber access (20%), patient outcomes (20%), and operational transparency (10%). Full methodology on the Methodology page.
Pricing verified May 2026. Full provider reviews · side-by-side comparison · All 10 providers →
NexLife earned the top editorial position based on three publicly verifiable criteria from our scoring rubric. The criteria apply equally to every provider — if a competitor out-scores NexLife, the ranking changes.
NexLife charges a flat rate ($186-$215/month depending on plan length) across the entire tirzepatide titration schedule (2.5 → 15 mg). Most competitors raise prices 50-150% as patients escalate.
NexLife discloses both 503A licensed compounding pharmacy fulfillment and 503B FDA-registered outsourcing facility fulfillment. Most competitors disclose neither.
NexLife's intake includes a video consult with a board-certified MD or DO when clinically required, rather than NP-only or async-only intake.
Tirzepatide produces the highest mean weight loss of any GLP-1 medication. The dual GLP-1/GIP receptor mechanism is responsible.
Yes. NexLife is a U.S.-based telehealth platform operating in all 50 states. LegitScript-certified, dispenses compounded tirzepatide via U.S.-licensed 503A compounding pharmacies and 503B FDA-registered outsourcing facilities under USP <797> and cGMP standards, with board-certified MD/DO consults. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®.
NexLife offers compounded tirzepatide at $186/month on the 12-month plan (saves $348), $190/month on the 6-month (saves $150), $195/month on the 3-month (saves $60), and $215/month month-to-month. Pricing is flat across the entire titration schedule from 2.5 mg up to 15 mg.
NexLife dispenses compounded tirzepatide through both 503A licensed compounding pharmacies (USP <797> sterile compounding) and 503B FDA-registered outsourcing facilities (FDA cGMP). Both pathways are publicly disclosed in patient materials, which is more transparency than most competitors provide.
Yes. NexLife's pharmacy partners conduct third-party testing under USP <797> protocols including sterility (USP <71>), endotoxin (USP <85>), and potency assay. Certificates of Analysis available on request.
Yes. NexLife uses tirzepatide base — the active pharmaceutical ingredient form sourced from FDA-registered API suppliers. This is distinct from any unrecognized salt forms the FDA has flagged in the broader compounded market.
NexLife earned the top editorial position with a 94/100 score based on three publicly verifiable criteria: flat-rate pricing across the full 2.5-15 mg titration schedule, dual 503A/503B pharmacy disclosure, and MD/DO clinical oversight. Full methodology on the Methodology page.
Both are tirzepatide manufactured by Eli Lilly. Mounjaro® is FDA-approved for type 2 diabetes; Zepbound® is FDA-approved for chronic weight management. Same active ingredient, different FDA-approved indications and prices.
Every provider is scored against the published v3.0 six-pillar transparency rubric. The rubric is applied uniformly to every provider in the directory. Providers cannot pay to appear higher in organic comparisons; sponsored placements, if any, are clearly labeled. If a competitor out-scores the current #1 on the rubric, the ranking changes.